Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | PARK7 | Q99497 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118444 | 0.90 | TP53 (0.42) | TP53MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5125044 | 0.88 | TP53 (0.40) | TP53MAPT | |
| SCHEMBL5219112 | 0.85 | TP53 (0.39) | TP53MAPTSMN1; SMN2ALDH1A1PARK7 | |
| SCHEMBL5114573 | 0.85 | LMNA (0.42) | TP53MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5117738 | 0.84 | TP53 (0.37) | TP53MAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5216357 | 0.83 | TP53 (0.41) | TP53MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5126197 | 0.82 | TP53 (0.39) | TP53MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5256018 | 0.82 | RARB (0.39) | TP53MAPTALDH1A1TSHRMEN1 | |
| SCHEMBL5111306 | 0.81 | TP53 (0.39) | TP53MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5118191 | 0.81 | TP53 (0.39) | TP53MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| EP-1828124-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063863-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | TP53 482/4885MAPT 3986/4885SMN1; SMN2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.